Nanoform Finland Oyj Bilan de santé

Santé financière contrôle des critères 6/6

Nanoform Finland Oyj possède un total de capitaux propres de €65.6M et une dette totale de €0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont €76.7M et de €11.1M.

Informations clés

Ratio d'endettement

€0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	€46.20m
Fonds propres	€65.57m
Total du passif	€11.10m
Total des actifs	€76.67m

Mises à jour récentes de la santé financière

Companies Like Nanoform Finland Oyj (HEL:NANOFH) Are In A Position To Invest In Growth

Jan 25

Recent updates

We Think Nanoform Finland Oyj (HEL:NANOFH) Can Afford To Drive Business Growth

Nov 07

We're Not Very Worried About Nanoform Finland Oyj's (HEL:NANOFH) Cash Burn Rate

Apr 28

We're Hopeful That Nanoform Finland Oyj (HEL:NANOFH) Will Use Its Cash Wisely

Nov 04

Companies Like Nanoform Finland Oyj (HEL:NANOFH) Are In A Position To Invest In Growth

Jan 25

What You Need To Know About Nanoform Finland Oyj's (HEL:NANOFH) Investor Composition

Dec 21

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de NANOFH ( €48.5M ) dépassent ses passifs à court terme ( €6.5M ).

Passif à long terme: Les actifs à court terme de NANOFH ( €48.5M ) dépassent ses passifs à long terme ( €4.5M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: NANOFH est sans dette.

Réduire la dette: NANOFH n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 9%.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: NANOFH dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: NANOFH dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 16.9 % chaque année

Nanoform Finland Oyj Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

We Think Nanoform Finland Oyj (HEL:NANOFH) Can Afford To Drive Business Growth

We're Not Very Worried About Nanoform Finland Oyj's (HEL:NANOFH) Cash Burn Rate

We're Hopeful That Nanoform Finland Oyj (HEL:NANOFH) Will Use Its Cash Wisely

Companies Like Nanoform Finland Oyj (HEL:NANOFH) Are In A Position To Invest In Growth

Recent updates

Consensus revenue estimates fall by 42%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Market cap size

New minor risk - Share price stability

Price target decreased by 9.1% to €4.00

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

First quarter 2024 earnings released: €0.09 loss per share (vs €0.06 loss in 1Q 2023)

New minor risk - Shareholder dilution

Nanoform Finland Oyj has filed a Follow-on Equity Offering.

Consensus revenue estimates decrease by 21%, EPS upgraded

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

New minor risk - Profitability

Nanoform Finland plc Receives Positive Results from its Own Pre- Clinical, In-Vivo Study of a Nanocrystalline-Enabled Apalutamide Oral Formulation

New major risk - Share price stability

Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide

Nanoform Finland plc Commences Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide

Forecast to breakeven in 2026

Nanoform Finland Oyj to Report Nine Months, 2024 Results on Nov 22, 2024

Consensus revenue estimates fall by 31%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think Nanoform Finland Oyj (HEL:NANOFH) Can Afford To Drive Business Growth

Consensus revenue estimates fall by 31%

No longer forecast to breakeven

Price target decreased by 16% to €6.00

Consensus revenue estimates decrease by 18%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Finnish Medicines Agency Renews Nanoform's GMP License and Nanoform Starts Clinical API Manufacturing of Blockbuster Medicine Candidate

We're Not Very Worried About Nanoform Finland Oyj's (HEL:NANOFH) Cash Burn Rate

Consensus revenue estimates fall by 37%

Price target decreased by 9.6% to €8.28

Forecast to breakeven in 2025

Nanoform Finland Oyj CTO Niklas Sandler Transitions to Technology Advisor to the CEO, effective, January 1, 2023

Nanoform Finland Oyj to Report Q3, 2023 Results on Nov 22, 2023

Nanoform Finland Oyj, Annual General Meeting, Apr 12, 2023

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Nanoform Finland Oyj (HEL:NANOFH) Will Use Its Cash Wisely

Consensus revenue estimates fall by 29%

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nanoform's Gonçalo Andrade Steps Down as Chief of Business Operations

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nanoform Finland Plc. Launches "STARMAP® Online" Placing AI-Power at the Fingertips of Medicine Developers

Nanoform Finland Plc. Launches "STARMAP® Online" Placing AI-Power at the Fingertips of Medicine Developers

Consensus forecasts updated

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Nanoform signs GMP manufacturing program with TargTex following formulation success

Companies Like Nanoform Finland Oyj (HEL:NANOFH) Are In A Position To Invest In Growth

Consensus revenue estimates fall to €2.05m

Third quarter 2021 earnings: EPS and revenues miss analyst expectations

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Second quarter 2021 earnings released: €0.07 loss per share (vs €0.14 loss in 2Q 2020)

First quarter 2021 earnings released: €0.06 loss per share (vs €0.12 loss in 1Q 2020)

Director has left the company

Nanoform Announces Completion and Final Results of Clinical Study

Nanoform Finland Oyj has completed a Follow-on Equity Offering in the amount of €40.000001 million.

Nanoform Finland Oyj to Report Q1, 2021 Results on May 27, 2021

Nanoform Finland Announces Further Positive Interim Results from Its Ongoing Clinical Study

New 90-day high: €7.73

New 90-day high: €7.40

Nanoform's Clinical Study Indicates Positive Interim Results

Nanoform Finland plc Announces First Dosing of Nanoformed Drug Successfully Accomplished

What You Need To Know About Nanoform Finland Oyj's (HEL:NANOFH) Investor Composition

Herantis Pharma Plc and Nanoform Finland Plc Signs Letter of Intent for Collaboration

New 90-day high: €4.59

Nanoform Launches Technology for Biologics and Sets New Near-Term Business Target for 2021

Nanoform Finland Oyj to Report Q3, 2020 Results on Nov 27, 2020

New 90-day low: €3.91

First half earnings released

Analyse de la situation financière

Historique et analyse du ratio d'endettement